11-Jan-2019

Proactive Investors speaks with Kazia CEO Dr James Garner

Our CEO, Dr James Garner sat down with Christine Corrado from Proactive Investors at the 11th Annual Biotech Showcase in San Francisco last week to discuss the multiple data readouts rapidly approaching for our GDC-0084 and Cantrixil clinical trial programs.

31-Oct-2018

Morgans interview with Kazia CEO Dr James Garner

Kazia Therapeutics CEO Dr James Garner was interviewed recently by Morgans Senior Analyst Scott Power about Kazia’s upcoming milestones and clinical trials.

24-Oct-2018

Potential glioblastoma therapy GDC-0084 presented to Finance News Network audience

Kazia Therapeutics CEO Dr James Garner was a key speaker at a Finance News Network event in Sydney last week.

25-Jul-2018

Sydney Shareholder Information Session July 2018

Kazia Therapeutics hosted briefing sessions for shareholders in Sydney and Melbourne this month.

11-Jul-2018

What makes our cancer therapies different

Kazia’s CEO Dr James Garner presented an overview of the company as a guest speaker at the 2018 Gold Coast Investment Showcase.

11-Jul-2018

Kazia’s CEO Dr James Garner presented an overview of the company as a guest speaker at the 2018 Gold Coast Investment Showcase

Kazia’s CEO Dr James Garner presented an overview of the company as a guest speaker at the 2018 Gold Coast Investment Showcase recently. Dr Garner’s presentation provides an excellent snapshot of the company at present and what makes its current therapies under development – Cantrixil for recurrent ovarian cancer and GDC-0084 for glioblastoma multiforme – different from existing treatment options and others in the clinic.

02-Jul-2018

Cantrixil phase 1 clinical study: Dr James Garner discusses the interim data

Kazia Therapeutics recently released preliminary data from its phase 1 clinical study of Cantrixil, a potential new treatment for recurrent ovarian cancer.

08-May-2018

Trials start on new treatment for ovarian cancer, the silent killer in Australia

A breakthrough new treatment for ovarian cancer that aims to stop the disease returning by killing off the cancer’s stem cells is undergoing safety trials in Australia.

03-May-2018

Meet our Scientific Advisory Board

Kazia was delighted recently to have the members of our Scientific Advisory Board gather in Sydney. We spent time working through details of our clinical trials for GDC-0084, our potential brain cancer therapeutic, and Cantrixil, our drug in development for ovarian cancer. Stuart Roberts, Senior Analyst at NDF Research took the opportunity to conduct wide-ranging interviews with each of the SAB members, which provide rich insights into their work. 

06-Apr-2018

Dr James Garner speaks with CommSec re our GDC-0084 Phase II trial start

Kazia Therapeutics (KZA) CEO, Dr James Garner discusses the progress of the company’s two drugs that are in development to treat brain & ovarian cancer.

29-Mar-2018

Why GDC-0084 for glioblastoma: Q&A with Kazia CEO Dr James Garner

Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) is developing its lead therapeutic program, GDC-0084, for the deadly brain cancer, glioblastoma multiforme (GBM).

29-Mar-2018

GDC-0084 and glioblastoma multiforme

Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) is developing a new therapy called GDC-0084 to treat the rare and deadly brain cancer, glioblastoma multiforme (GBM).

29-Mar-2018

NDF Research Senior Analyst Stuart Roberts interviews Kazia Therapeutics CEO Dr James Garner as the GDC-0084 phase II trial launches in the US

Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) is developing its lead therapeutic program, GDC-0084, for the deadly brain cancer, glioblastoma multiforme (GBM).

04-Jul-2017

CommSec Executive Series interviews CEO Dr James Garner on benefits of new business model for patients

CommSec's Tom Piotrowski speaks with Novogen Ltd (NRT) CEO & Executive Director, Dr James Garner about the company’s key milestones over the past 12 months and the clinical trials for its brain cancer treatment drug.

01-May-2017

Dr James Garner, CEO, speaks to Canary Networks investment forum

Novogen (ASX: NRT), Chief Executive Officer & Executive Director Dr James Garner , gives an update on Novogen since coming on board in 2016.

30-Jan-2017

CommSec interview re our new name, Kazia Therapeutics and our clinical trial progress

CommSec's Tom Piotrowski speaks with Kazia Therapeutics (KZA) CEO & Managing Director, Dr James Garner about the company’s recent name change from Novogen and progress of its ovarian cancer and brain cancer drug trials.

31-Oct-2016

Sky News Interview – In-licensing of GDC-0084

Novogen Sky News Interview